| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/12/2010 | CA2545878C Compositions and methods for treating a posterior segment of an eye |
| 01/12/2010 | CA2545128C Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
| 01/12/2010 | CA2516621C Method for increasing hair growth using a creatine compound |
| 01/12/2010 | CA2511242C Inhibitors of human tumor-expressed ccxckr2 |
| 01/12/2010 | CA2483678C 6-11 bicyclic ketolide derivatives |
| 01/12/2010 | CA2481461C Derivatives of n-[phenyl(piperidin-2-yl) methyl] benzamide, the preparation method thereof and application of same in therapeutics |
| 01/12/2010 | CA2468412C 17.alpha.-alkyl-17.beta.-oxy-estratrienes and intermediates for their production, use of the 17.alpha.-alkyl-17.beta.-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations |
| 01/12/2010 | CA2466338C New uses for anti-malarial therapeutic agents |
| 01/12/2010 | CA2461946C Combinations for the treatment of immunoinflammatory disorders |
| 01/12/2010 | CA2457351C Quinazolinone derivatives |
| 01/12/2010 | CA2442906C Reconstitutable parenteral composition containing a cox-2 inhibitor |
| 01/12/2010 | CA2439831C Polymorphic and other crystalline forms of cis-ftc |
| 01/12/2010 | CA2427467C Sn-38 lipid complexes and methods of use |
| 01/12/2010 | CA2421040C Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
| 01/12/2010 | CA2411418C Hydroxyformamidine derivatives and medicines containing the same |
| 01/12/2010 | CA2409664C Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 01/12/2010 | CA2407838C Pyrano, piperidino, and thiopyrano compounds and methods of use |
| 01/12/2010 | CA2407463C N-substituted peptidyl nitriles as cysteine cathepsin inhibitors |
| 01/12/2010 | CA2403835C Anti-viral pyrimidine nucleoside analogues |
| 01/12/2010 | CA2403514C 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 01/12/2010 | CA2399818C Preventive and therapeutic medicament for gastroesophageal reflux disease |
| 01/12/2010 | CA2398405C Chromatographic separation method of paclitaxel and cephalomannin |
| 01/12/2010 | CA2391643C Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors |
| 01/12/2010 | CA2387675C Novel hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 01/12/2010 | CA2384018C Muscarinic antagonists |
| 01/12/2010 | CA2373936C Nasogastric enteral formulations |
| 01/12/2010 | CA2368653C Z-styryl sulfone anticancer agents |
| 01/12/2010 | CA2346010C Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance |
| 01/12/2010 | CA2331846C Expression vectors for stimulating an immune response and methods of using the same |
| 01/12/2010 | CA2324339C Piperidine derivatives |
| 01/12/2010 | CA2306428C 3-oxo-2(h)-1,2,4 - triazine derivatives as ligands of 5ht1a receptors |
| 01/12/2010 | CA2287219C 2-oxo-1-azetidine sulfonic acid derivatives as potent .beta.-lactamase inhibitors |
| 01/12/2010 | CA2279267C Use of 15-ketoprostaglandin e compounds as endothelin antagonist |
| 01/12/2010 | CA2276373C Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
| 01/12/2010 | CA2254954C Morphogen treatment for chronic renal failure |
| 01/12/2010 | CA2197435C Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias |
| 01/12/2010 | CA2192089C Inhibitors of interleukin-1.beta. converting enzyme |
| 01/12/2010 | CA2154124C Methods and compositions for treating wounds |
| 01/11/2010 | CA2641297A1 Pyrazine derivatives, methods of use, and methods for preparing same |
| 01/08/2010 | CA2671115A1 Hydrogels suitable for use in polyp removal |
| 01/07/2010 | WO2010003133A2 Cdk modulators |
| 01/07/2010 | WO2010003127A2 Antagonists of prostaglandin d2 receptors |
| 01/07/2010 | WO2010003120A2 Antagonists of prostaglandin d2 receptors |
| 01/07/2010 | WO2010003114A1 Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| 01/07/2010 | WO2010003092A1 Methods and compositions for reducing inflammation and treating inflammatory disorders |
| 01/07/2010 | WO2010003084A2 Phosphodiesterase 4 inhibitors |
| 01/07/2010 | WO2010003078A2 Melt granulation process |
| 01/07/2010 | WO2010003057A2 Treating cancer |
| 01/07/2010 | WO2010003055A1 Compounds and methods for treating disorders related to glucose metabolism |
| 01/07/2010 | WO2010003048A1 Benzimidazoles and related analogs as sirtuin modulators |
| 01/07/2010 | WO2010003046A2 Gabapentin enacarbil salts and processes for their preparation |
| 01/07/2010 | WO2010003025A1 Bicyclic heterocycles as mek kinase inhibitors |
| 01/07/2010 | WO2010003022A1 Isoindolone derivatives as mek kinase inhibitors and methods of use |
| 01/07/2010 | WO2010002998A1 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
| 01/07/2010 | WO2010002985A1 Bmi-1 protein expression modulators |
| 01/07/2010 | WO2010002971A1 Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands |
| 01/07/2010 | WO2010002970A2 Isolation of cyclopamine |
| 01/07/2010 | WO2010002965A2 Pneumonia treatment |
| 01/07/2010 | WO2010002956A2 Heterocyclic derivatives as modulators of ion channels |
| 01/07/2010 | WO2010002954A1 (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 01/07/2010 | WO2010002937A1 Formulations of 5-fluorocytosine and uses thereof |
| 01/07/2010 | WO2010002880A1 Topical steroidal formulations |
| 01/07/2010 | WO2010002877A2 Bycyclic nucleosides and nucleotides as therapeutic agents |
| 01/07/2010 | WO2010002869A1 2-oxo-1-pyrrolidine derivatives |
| 01/07/2010 | WO2010002851A1 Silencing and rig-1 activation by dual function oligonucleotides |
| 01/07/2010 | WO2010002845A2 Quinazoline derivatives |
| 01/07/2010 | WO2010002820A1 Aza-indoles and related compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| 01/07/2010 | WO2010002802A1 Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| 01/07/2010 | WO2010002779A2 Naphthyridininones as aurora kinase inhibitors |
| 01/07/2010 | WO2010002777A2 Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
| 01/07/2010 | WO2010002774A1 Process for the preparation of substituted pyrimidine derivatives |
| 01/07/2010 | WO2010002763A1 Solid dosage formulations of telcagepant potassium |
| 01/07/2010 | WO2010002675A2 Quinine sulfate/bisulfate solid complex; methods of making; and methods of use thereof |
| 01/07/2010 | WO2010002655A2 Compounds and compositions as kinase inhibitors |
| 01/07/2010 | WO2010002563A1 Methods and ophtalmic devices used in the treatment of ocular allergies |
| 01/07/2010 | WO2010002483A1 Optionally condensed dihydro pyridine, dihydropyrimidine and dihydro pyrane derivatives acting as late sodium channel blockers |
| 01/07/2010 | WO2010002473A1 Unit dosage of apadenoson |
| 01/07/2010 | WO2010002472A1 Jak kinase modulating compounds and methods of use thereof |
| 01/07/2010 | WO2010002465A2 Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase |
| 01/07/2010 | WO2010002454A2 Therapeutic combinations for use in neoplasia |
| 01/07/2010 | WO2010002451A1 Naphthyridin derivatives |
| 01/07/2010 | WO2010002438A1 Ionic liquid epoxy resins |
| 01/07/2010 | WO2010002429A1 Synergistic antimicrobial mixtures |
| 01/07/2010 | WO2010002415A1 Treatment of antibiotic-resistant bacteria infection |
| 01/07/2010 | WO2010002244A1 Nutritional composition for infants delivered via caesarean section |
| 01/07/2010 | WO2010002241A1 Nutritional composition for infants delivered via caesarean section |
| 01/07/2010 | WO2010002209A2 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same |
| 01/07/2010 | WO2010002093A1 Pharmaceutical composition for preventing and treating a side effect of levodopa which is a therapeutic agent for parkinson’s disease |
| 01/07/2010 | WO2010002010A1 Novel spirochromanone carboxylic acids |
| 01/07/2010 | WO2010001990A1 Tetracyclic compound |
| 01/07/2010 | WO2010001989A1 Agent for reducing cancer stem cell and/or cancer progenitor cell, and agent for preventing recurrence and/or metastasis of cancer |
| 01/07/2010 | WO2010001946A1 Triazole derivative or salt thereof |
| 01/07/2010 | WO2010001932A1 Pharmaceutical composition containing surface-coated microparticles |
| 01/07/2010 | WO2010001930A1 Solid preparation for internal application |
| 01/07/2010 | WO2010001926A1 Water-containing composition |
| 01/07/2010 | WO2010001909A1 Double-stranded polynucleotide |
| 01/07/2010 | WO2010001869A1 Tetra-substituted benzene compound and use thereof |
| 01/07/2010 | WO2010001824A1 Novel antischistosomal agent |
| 01/07/2010 | WO2010001821A1 Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative and use of the pharmaceutical composition |
| 01/07/2010 | WO2010001574A1 Process for production of spherical microparticles comprising tamsulosin hydrochloride |